Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Glucagon-like peptide-1 (GLP-1) agonists represent one of the most significant pharmaceutical breakthroughs of the past two decades. The journey from laboratory discovery to widespread clinical adoption spans decades of research, regulatory milestones, and real-world outcomes that have transformed how patients manage weight and blood sugar control.

The Origins of GLP-1 Discovery and Early Research

Scientists first identified GLP-1 as a natural hormone in the human intestine during the 1980s. This peptide, produced by enteroendocrine cells in response to nutrient intake, plays a central role in regulating appetite, insulin secretion, and glucose metabolism. Researchers recognized that mimicking GLP-1's effects could offer therapeutic benefits for both type 2 diabetes and weight management, sparking decades of drug development focused on creating stable, synthetic versions.

Early attempts to develop GLP-1 therapies faced a critical obstacle: the hormone degrades rapidly in the bloodstream. Scientists needed to engineer compounds that could resist enzymatic breakdown while maintaining the biological activity that made GLP-1 so metabolically powerful. This challenge drove innovation in peptide chemistry and led to the creation of longer-acting formulations that could remain effective in the body for days or weeks.

When the First GLP-1 Agonist Received FDA Approval

Exenatide became the first GLP-1 receptor agonist approved by the FDA in 2005 under the brand name Byetta. This injectable medication represented a breakthrough for type 2 diabetes patients and demonstrated clinical proof that GLP-1 mimetics could achieve meaningful reductions in blood sugar and body weight. The approval validated years of preclinical research and opened the door for subsequent generations of GLP-1 drugs with improved efficacy and convenience profiles.

Following exenatide's market entry, the GLP-1 class expanded rapidly. Liraglutide launched in 2009, offering once-daily dosing instead of twice-daily injections. Dulaglutide arrived in 2014 as a once-weekly option. Each new formulation built on prior safety data while addressing practical patient needs like injection frequency and ease of use. These advances reflected the competitive race among manufacturers to establish market dominance in an increasingly valuable therapeutic category.

Semaglutide and the Modern Era of GLP-1 Therapy

Semaglutide, developed by Novo Nordisk, entered the market in 2017 and quickly became the dominant GLP-1 treatment option. Clinical trials demonstrated superior weight loss outcomes compared to earlier-generation compounds, with some patients achieving reductions exceeding 15 percent of baseline body weight. Semaglutide's once-weekly injection schedule and potent metabolic effects made it the preferred choice for both diabetes management and weight loss across diverse patient populations.

PlexusDx delivers compounded semaglutide injection through licensed 503A pharmacies, starting at $149 per month across all commitment tiers. This pricing model eliminates dose-based increases—your dose may need to go up, but your price won't. PlexusDx also offers oral semaglutide as an alternative for patients preferring tablet formulations, expanding access to this proven therapy regardless of injection preference.

Tirzepatide: The Next Generation Dual-Action GLP-1

Tirzepatide, approved by the FDA in 2022, represents the newest evolution in GLP-1 technology. Unlike traditional GLP-1 agonists that target a single receptor pathway, tirzepatide simultaneously activates both GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptors. Clinical trials showed tirzepatide achieves weight loss rates averaging 20-22 percent—substantially higher than first-generation GLP-1 drugs—making it a game-changing option for patients seeking maximum metabolic impact.

PlexusDx offers compounded tirzepatide injection starting at $249 per month, with an oral formulation available at $279 monthly. For patients seeking synergistic benefits, PlexusDx GLP-Squared combines semaglutide and tirzepatide in a single injection, starting at $249 per month. All PlexusDx peptide therapies are compounded through licensed 503A pharmacies and available in all 50 states without insurance requirements or membership fees.

How Genetic Testing Personalizes Your GLP-1 Response

Not all patients respond identically to GLP-1 therapy, and genetic variation significantly influences treatment outcomes. PlexusDx Precision Peptide Genetic Test identifies individual predispositions across 14 metabolic pathways, 49 peptides, and 150+ genetic insights—including critical variants like GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313. These genetic markers predict your natural responsiveness to GLP-1 signaling and help identify which formulation (semaglutide, tirzepatide, or dual-action) offers optimal effectiveness for your unique biology.

The Precision Peptide Genetic Test costs $99 as an add-on after your first month of treatment. This testing enables precision health dosing and compound selection, moving beyond one-size-fits-all approaches to truly personalized GLP-1 therapy. Understanding your genetic peptide pathways transforms your weight loss journey from trial-and-error to evidence-based optimization.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What year did the first GLP-1 agonist drug come out for patients?

Exenatide (Byetta) received FDA approval in 2005 as the first GLP-1 receptor agonist available to patients. This injectable medication marked the beginning of a new therapeutic class for type 2 diabetes and weight management. Modern versions like semaglutide and tirzepatide now offer improved efficacy and convenience compared to these pioneering drugs.

How does semaglutide work differently than the first GLP-1 drugs?

Semaglutide (approved 2017) features 94% amino acid homology to native GLP-1, allowing prolonged receptor activation and once-weekly dosing. Early GLP-1 drugs like exenatide required twice-daily injections and achieved more modest weight loss. Semaglutide's superior pharmacokinetics enable sustained appetite suppression and greater metabolic benefits, which is why PlexusDx features compounded semaglutide starting at $149 per month.

Is tirzepatide more effective than semaglutide for weight loss?

Clinical trials show tirzepatide achieves 20-22% weight loss versus 14-17% for semaglutide, because tirzepatide activates both GLP-1 and GIP receptors simultaneously. This dual-pathway mechanism produces greater appetite suppression and improved metabolic control. PlexusDx offers tirzepatide injection at $249/month or GLP-Squared dual-compound therapy at the same price for maximum synergistic benefits.

Can I use PlexusDx GLP-1 therapy if I don't have insurance?

Yes. PlexusDx serves all 50 states without insurance requirements, membership fees, or prior authorization delays. Compounded semaglutide starts at $149/month, and all formulations are HSA/FSA eligible. This direct-access model makes prescription-grade GLP-1 therapy affordable and accessible regardless of insurance status.

How does genetic testing improve my GLP-1 treatment results?

PlexusDx Precision Peptide Genetic Test identifies your unique variants across 14 metabolic pathways and 49 peptides, predicting your natural GLP-1 responsiveness. Testing for markers like GLP1R rs6923761 and GIPR rs1800437 helps determine whether semaglutide, tirzepatide, or microdose protocols will work best for your biology. At $99 after your first month, genetic testing personalizes your pathway to sustainable weight loss.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves